Stemedica Cell Technologies, Inc. is a global leader in regenerative medicine. Incorporated in 2005 by a group of prominent scientists, clinicians and executives, the Company’s allogeneic cellular products are based on over thirty years of research, manufacturing innovation and clinical application. Stemedica manufactures and distributes mesenchymal stem cells and neural stem cells for use in pre-clinical and clinical trials both nationally and internationally.
Stemedica’s unparalleled proprietary low-oxygen manufacturing process produces best-in-class, clinical grade, allogeneic stem cell lines. Stemedica’s live biologic products and stem cell derived factors are manufactured in our government licensed, cGMP facility. As a result of our dynamic manufacturing process and unique product attributes, our cells are being used in advanced human clinical trials for multiple medical indications. These trials are among the most innovative and promising translational stem cell studies in the industry.
“At Stemedica, we believe that today’s most advanced clinicians and researchers deserve superior stem cell products to fuel their work. It is this belief that drives our mission: “To develop and manufacture the best ischemic tolerant allogeneic stem cells available in the advancement of science and medicine.”
Roger J. Howe, PhD